Loading
Insight Molecular Diagnostics Inc. Stock: price and insider trades · United States
US·Mcap US$98.5M
No insider purchase over the last 90 days. The latest was filed 27 Apr 2026.
Insight Molecular Diagnostics Inc.: what insiders have been doing
This page follows insider dealings at Insight Molecular Diagnostics Inc. as filed with SEC (Form 4). The last twelve months, up to 18 October 2026, brought 22 filings signed by 7 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 13 purchases totalling €4.8M. The totals exclude 6 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 major shareholder. At €2.5M, the purchase published on 12 February 2026 by Broadwood Partners, L.P. is the largest of the period.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 22 filings, this issuer sits right on that mark. Our records for Insight Molecular Diagnostics Inc. go back to 2021, with 44 purchases and 1 sale on the open market in total. The 10-K for the year ended 31 December 2025 shows 4.1 m USD of revenue and -50.2 m USD of net income.
The last insider purchase was made public on 27 April 2026, 174 days ago. The median gap between a trade and its publication by SEC (Form 4) is 4 days. For comparison, the SEC allows two business days to file a Form 4.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
90
Thresholds
n/a
Buy Volume
€36M
44 ops. · all time
Sell Volume
€10,958
1 ops. · all time
Who traded when
BuySaleBroadwood Partners, L.P.14 buys
Patrick W. Smith5 buys
Andrea S. James2 buys
Andrew Arno1 buy
Since the insiders bought
- +11.6%Entry US$0.03 · Close at T+90 US$0.03
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Insight Molecular Diagnostics Inc. Buy (bullish), based on 4 analysts. Average price target: US$8.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.01
Analyst consensus
4 analystsBuy
US$4.00Target US$8.25(+174%)US$12.00
Income statement
RevenueUS$4.1M
Gross profitUS$2.3M57% margin
EBITDA-US$47.9M-1182% margin
Net income-US$50.2M-1238.5% margin
Valuation
PER (forward)-3.8x
Beta1.81
Balance sheet & cash
Market capUS$98.5M
Total debtUS$3.5M
Free Cash Flow-US$25.4M
Profitability & ownership
ROA-57.8%
% insiders21.0%
% institutions57.5%
Last declaration on 6 July 2026
Declarations90 total
12,100 shares@ US$5.698.08% mcap100.0% of flowCommon Stock, no par valueSEC:0001493152-26-032231:0
7,700 shares@ US$5.695.14% mcap100.0% of flowCommon Stock, no par valueSEC:0001493152-26-032233:0
7,700 shares@ US$5.695.14% mcap100.0% of flowCommon Stock, no par valueSEC:0001493152-26-032235:0
32,331 sharesCommon Stock, no par valueSEC:0001493152-26-028753:0
280,381 shares@ US$3.502517.5% of flowCommon Stock, no par valueSEC:0000919574-26-002414:0
Canonical exit: 22 Jul 2026 (T+90)
38,880 shares@ US$3.52582.4% of flowCommon Stock, no par valueSEC:0000919574-26-002414:2
Canonical exit: 23 Jul 2026 (T+90)
250,923 shares@ US$3.639116.2% of flowCommon Stock, no par valueSEC:0000919574-26-002414:4
Canonical exit: 26 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002414:1
Canonical exit: 22 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002414:3
Canonical exit: 23 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002414:5
Canonical exit: 26 Jul 2026 (T+90)
102,057 shares@ US$3.44576.2% of flowCommon Stock, no par valueSEC:0000919574-26-002306:0
Canonical exit: 15 Jul 2026 (T+90)
40,690 shares@ US$3.88222.8% of flowCommon Stock, no par valueSEC:0000919574-26-002306:4
Canonical exit: 19 Jul 2026 (T+90)
40,114 shares@ US$3.57112.5% of flowCommon Stock, no par valueSEC:0000919574-26-002306:2
Canonical exit: 16 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002306:1
Canonical exit: 15 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002306:3
Canonical exit: 16 Jul 2026 (T+90)
00Common Stock, no par valueSEC:0000919574-26-002306:5
Canonical exit: 19 Jul 2026 (T+90)
28,302 sharesCommon StockSEC:0001493152-26-013574:0
6,289 sharesCommon StockSEC:0001493152-26-013572:0
47,170 sharesCommon StockSEC:0001493152-26-013571:0
521,739 shares@ US$5.7552.4% of flowCommon Stock, no par valueSEC:0000919574-26-000779:0
Canonical exit: 11 May 2026 (T+90)
50,000 shares0Common StockSEC:0001493152-25-022358:0
50,000 shares0Common StockSEC:0001493152-25-020719:0
35,000 shares0Common Stock, no par valueSEC:0001641172-25-017787:0
55,000 shares0Common Stock, no par valueSEC:0001641172-25-017798:0
35,000 shares0Common Stock, no par valueSEC:0001641172-25-017796:0
25 of 90 declarations
About Insight Molecular Diagnostics Inc.
Insight Molecular Diagnostics Inc. is a company focused on developing molecular diagnostic tests. It aims to enhance healthcare through innovative solutions.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
